Anthem Biosciences Limited
ANTHEM · General/Diversified · NSE
₹722
Current Market Price
Fair Value (DCF)
₹172
Margin of Safety
-76.1%
Updated just now
YieldIQ Score
53/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
57%
ROE
18.7%
Debt/Equity
0.00
WACC
12.8%
Market Cap
₹0.41 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
26.9%
Return on capital employed
EV / EBITDA
48.8×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
66.6×
EBIT covers interest
Current Ratio
5.32×
Short-term liquidity
Asset Turnover
0.60×
Revenue per ₹ of assets
Revenue CAGR (3Y)
22.7%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹722.05
Bear case
₹108.27
MoS -566.9%
Base case
₹172.25
MoS -319.2%
Bull case
₹211.31
MoS -241.7%
Ratio Trends
ANTHEM · last 4 annual periods
ROE
18.7%
ROCE
30.0%
Operating Margin
—
Debt / Equity
0.05×
PE
—
EV / EBITDA
—
Historical Financials
ANTHEM · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹1231 Cr | ₹1057 Cr | ₹1419 Cr | ₹1845 Cr | +14.4% |
| EBITDA | ₹616 Cr | ₹569 Cr | ₹568 Cr | ₹756 Cr | +7.1% |
| EBIT | — | — | — | — | — |
| PAT | ₹406 Cr | ₹385 Cr | ₹367 Cr | ₹451 Cr | +3.6% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹333 Cr | ₹306 Cr | ₹140 Cr | ₹418 Cr | +7.9% |
| CapEx | ₹-161 Cr | ₹-195 Cr | ₹-297 Cr | ₹-315 Cr | — |
| FCF | ₹172 Cr | ₹111 Cr | ₹-157 Cr | ₹104 Cr | -15.6% |
| Total Assets | ₹1619 Cr | ₹2014 Cr | ₹2398 Cr | ₹2808 Cr | +20.1% |
| Total Debt | ₹37.8 Cr | ₹126 Cr | ₹239 Cr | ₹113 Cr | +44.2% |
| Shareholders' Equity | ₹1355 Cr | ₹1741 Cr | ₹1925 Cr | ₹2410 Cr | +21.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ANTHEM vs 1 closest peer by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| BIOCON Biocon Limited | -71.1% | 32 | Overvalued | 365.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for ANTHEM in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Anthem Biosciences Limited (ANTHEM.NS) trades at 722.05 vs a model fair value of 172.25, a gap of -76.1%. Piotroski F-score: 7/9. Moat la...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ANTHEM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ANTHEM →
Compare
Head-to-head with peers
Compare ANTHEM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ANTHEMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.